Glenmark Pharma shares gain 10%, hit upper circuit limit
Glenmark Pharma Share Price: Shares of Glenmark Pharmaceuticals Ltd surged 10 per cent on Friday after the company announced that it has signed an up to USD 2 billion deal with AbbVie to commercialise its under-development drug for treating cancer and autoimmune diseases, in one of the biggest transactions in the pharma sector.
The stock rose 9.99 per cent to hit a fresh 52-week high and upper circuit limit of Rs 2,095.65 on the BSE.
On the NSE, the stock rose 10 per cent to Rs 2,094.40 - its fresh 52-week high and upper circuit limit.
Ichnos Glenmark Innovation, an arm of Glenmark Pharmaceuticals, has signed an agreement for its key investigational asset 'ISB 2001'.
ISB 2001, intended for the treatment of cancer and autoimmune diseases, has been developed for oncology and aut...










